1:26 PM
Jul 11, 2018
 |  BC Extra  |  Politics & Policy

More scrutiny for value-based CAR T models

A letter from Rep. Elijah Cummings (D-Md.) to Office of Management and Budget Director Mick Mulvaney on Wednesday has increased concerns that biopharmas could face greater scrutiny when negotiating value-based pricing arrangements with CMS.

Cummings cited a conflict of interest between the office's associate director, Joseph Grogan, and CMS negotiations of a proposed demonstration project by Novartis AG (NYSE:NVS; SIX:NOVN) for CAR T therapy Kymriah tisagenlecleucel. Grogan was previously an employee of Gilead Sciences Inc. (NASDAQ:GILD), which also develops CAR T therapies.

The letter comes two days after CMS said it had canceled the Novartis pilot this year.

In his letter, Cummings said Grogan’s employment history at Gilead and his role on the Kymriah demonstration project while...

Read the full 579 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >